Last edition
News about
Adimab Collaborator GSK Receives Additional Marketing Approval for Depemokimab
Adimab Collaborator GSK has received additional marketing approval for depemokimab, marking the sixth collaborator program to reach the market and strengthening its biologics portfolio.
Aurobindo Pharma Secures US FDA Approval for Glycerol Phenylbutyrate Oral Liquid 1.1 g/mL
Aurobindo Pharma has secured USFDA approval for Glycerol Phenylbutyrate Oral Liquid 1.1 g/mL, to be manufactured at its Unit-III facility, with immediate launch planned to strengthen its specialty pharma portfolio.
The US Food and Drug Administration reviews concerns over Ocrevus, as safety and efficacy questions emerge for its use in primary progressive multiple sclerosis patients.
The partnership among Orbicular Pharmaceutical Technologies, Gland Pharma and Apotex, achieves first ANDA approval with Competitive Generic Therapy designation, gaining six-month exclusivity for complex multivitamin injectable in the United States.
GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021
Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.
NIPER Mohali Partners with Novartis to Support Faculty Research
NIPER Mohali signs grant agreement with Novartis Healthcare to support faculty research through development pioneer grant, strengthen industry-academia synergy, and boost innovation and R&D capabilities.
Samsung Bioepis Starts Phase 1 Trial for Nectin-4 ADC SBE303
Samsung Bioepis launches Phase 1 trial of SBE303, a Nectin-4 targeting ADC, marking a key step in advancing its oncology pipeline and Antibody-Drug Conjugate development.
GSK Acquires 100 Percent Equity of 35Pharma for USD 950 Million
GSK completes acquisition of 35Pharma, adding HS235, a potential best-in-class therapy for Pulmonary Hypertension.
PrecisionLife and Ovation Partner to Launch GLP-1 stratification LDT and GLP-1 DNA Test in H2 2026
PrecisionLife and Ovation partner to launch GLP-1 stratification LDT and consumer DNA test in 2026, with early data showing distinct genetic markers for weight loss and glycemic control.
Travere Secures Full US FDA Approval for FILSPARI
Travere Therapeutics secures full US FDA approval for FILSPARI (sparsentan) to treat FSGS, expanding access to over 100,000 patients with a therapy aligned with KDIGO guidelines.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy